Literature DB >> 7618107

Inactivation of the mouse Huntington's disease gene homolog Hdh.

M P Duyao1, A B Auerbach, A Ryan, F Persichetti, G T Barnes, S M McNeil, P Ge, J P Vonsattel, J F Gusella, A L Joyner.   

Abstract

Huntington's disease (HD) is a dominant neurodegenerative disorder caused by expansion of a CAG repeat in the gene encoding huntingtin, a protein of unknown function. To distinguish between "loss of function" and "gain of function" models of HD, the murine HD homolog Hdh was inactivated by gene targeting. Mice heterozygous for Hdh inactivation were phenotypically normal, whereas homozygosity resulted in embryonic death. Homozygotes displayed abnormal gastrulation at embryonic day 7.5 and were resorbing by day 8.5. Thus, huntingtin is critical early in embryonic development, before the emergence of the nervous system. That Hdh inactivation does not mimic adult HD neuropathology suggests that the human disease involves a gain of function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7618107     DOI: 10.1126/science.7618107

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  204 in total

1.  Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.

Authors:  J M Lecerf; T L Shirley; Q Zhu; A Kazantsev; P Amersdorfer; D E Housman; A Messer; J S Huston
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

Review 2.  Transgenic models of Huntington's disease.

Authors:  K Sathasivam; C Hobbs; L Mangiarini; A Mahal; M Turmaine; P Doherty; S W Davies; G P Bates
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

3.  Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Authors:  P H Reddy; V Charles; M Williams; G Miller; W O Whetsell; D A Tagle
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

4.  An upstream open reading frame impedes translation of the huntingtin gene.

Authors:  Joseph Lee; Eun Hee Park; Graeme Couture; Isabelle Harvey; Philippe Garneau; Jerry Pelletier
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

5.  Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14.

Authors:  Kun Huang; Shaun S Sanders; Rujun Kang; Jeffrey B Carroll; Liza Sutton; Junmei Wan; Roshni Singaraja; Fiona B Young; Lili Liu; Alaa El-Husseini; Nicholas G Davis; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2011-06-02       Impact factor: 6.150

Review 6.  Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts?

Authors:  D C Rubinsztein; A Wyttenbach; J Rankin
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

Review 7.  Huntingtin in health and disease.

Authors:  Anne B Young
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 8.  Huntington's disease: a decade beyond gene discovery.

Authors:  Penelope Hogarth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

Review 9.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

Review 10.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.